Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02515097 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 213
- Enrollment target
NCT02515097: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT02515097 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 213 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02515097, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 213 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Primary Outcome
Treatment success defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to "clear" or "almost clear" at Week 8. The IGA score was based on a 5-point scale ranging from 0 to 4 (0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe). The face, scalp, palms, soles, axillae, and intertriginous areas were excluded from this assessment.
Interventions
- DRUG IDP-122 Lotion
- DRUG IDP-122 Vehicle Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2015-11-05 |
| Est. Completion | 2017-03-15 |
| Phase | Phase 3 |
What the finished NCT02515097 record still lists
NCT02515097 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which IDP-122 Lotion is the first listed.
NCT02515097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02515097 about?
NCT02515097 is a clinical study titled "Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis". This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
What is the current status of trial NCT02515097?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 213 participants. The study started on 2015-11-05. Estimated completion is 2017-03-15.
What interventions are being tested in trial NCT02515097?
The interventions under investigation include: IDP-122 Lotion (DRUG), IDP-122 Vehicle Lotion (DRUG).
Who is sponsoring clinical trial NCT02515097?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02515097's enrollment target sits among peer trials
213 1335th of 2000 higher than 666 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI